1. Introduction

Biosimilar interchangeability is a regulatory and legal concept determining when a biosimilar biological medicine may be substituted for its reference biological product, subject to the applicable jurisdiction's laws and pharmacy rules.

A biosimilar is a biological medicine demonstrated to be highly similar to an already authorised reference product, with no clinically meaningful differences in safety, purity and potency. Because biological medicines are produced using living systems and can exhibit natural molecular variability, they are not assessed in exactly the same way as conventional generic medicines.

Interchangeability law addresses several distinct questions:

Scientific similarity: Is the biosimilar sufficiently similar to the reference product?

Regulatory approval: Has the competent authority authorised the product for the intended indications?

Interchangeability designation: Has the additional legal or scientific threshold for substitution been satisfied, where required?

Pharmacy substitution: May a pharmacist dispense the alternative without obtaining a new prescription or prescriber approval?

Liability and patient protection: Who is responsible if substitution causes harm, treatment failure or a medication error?

The most important legal distinction is that biosimilar approval and interchangeability are not universally equivalent. The legal effect depends on the jurisdiction.

2. Meaning and scope of the legal threshold

The legal threshold is the collection of scientific evidence, regulatory findings and procedural conditions that must be satisfied before a biosimilar can receive an interchangeability designation or be substituted under applicable law.

The five principal thresholds

1. Analytical similarity

Extensive structural and functional evidence establishes high similarity to the reference biologic.

2. Clinical and immunogenicity assessment

Evidence must support comparable clinical performance and address the possibility of immune responses.

3. Regulatory determination

The competent authority decides whether the product meets the applicable approval and interchangeability standards.

4. Substitution authority

National or state law determines whether the product can be substituted, by whom, and under what conditions.

5. Continuing accountability

Traceability, pharmacovigilance, recordkeeping and appropriate communication help manage post-substitution risks.

These are related but distinct requirements. Not every jurisdiction requires a separate interchangeability designation, and not every product requires the same clinical studies.

3. United States: statutory interchangeability standard

The United States provides the clearest example of a separate statutory interchangeability designation.

A. Governing legislation

The principal legal instruments are:

Public Health Service Act (PHSA), § 351(k), codified at 42 U.S.C. § 262(k).

Biologics Price Competition and Innovation Act of 2009 (BPCIA).

FDA regulations and guidance concerning biosimilar development and interchangeability.

State pharmacy-substitution laws governing the actual dispensing of interchangeable products.

Under PHSA § 351(k)(4), an applicant seeking interchangeability must establish two core elements.

First: same clinical result. The product must be expected to produce the same clinical result as the reference product in any given patient.

Second: switching safety. For a product administered more than once to an individual, the risk in terms of safety or diminished efficacy from alternating or switching between the biosimilar and reference product must not be greater than the risk from using the reference product without that alternation or switching.

The FDA explains these requirements in its official interchangeability guidance.

FDA+1

B. How the threshold operates

An important qualification: FDA guidance has historically discussed switching studies, but the agency does not invariably require a new, dedicated switching clinical trial in every application. The evidence needed depends on the product, available data, scientific justification and current regulatory requirements.

C. Does interchangeability mean superior safety?

No. An interchangeable biosimilar is not necessarily safer or more effective than an FDA-approved biosimilar that lacks the interchangeable designation. Both must satisfy the applicable biosimilarity standard. The additional designation has a particular legal function: enabling pharmacy-level substitution where state law permits.

FDA+1

4. India: regulatory approval versus pharmacy substitution

India requires a different legal analysis.

The principal regulatory framework includes the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, applicable licensing requirements, and the CDSCO's Guidelines on Similar Biologics.

The CDSCO and Department of Biotechnology published revised guidelines in 2025, replacing the 2016 guidelines. These update the scientific approach to evaluating similarity, particularly analytical methods, in-vitro studies and the need for non-clinical studies.

CDSCO+1

A. What the Indian threshold requires

In general, the manufacturer must demonstrate that the proposed similar biologic meets the relevant quality, safety and efficacy requirements for marketing authorisation. The evidence may include:

Comparative structural and physicochemical characterisation.

Biological activity and functional comparability.

Appropriate non-clinical evidence where needed.

Clinical evidence and immunogenicity assessment justified by the product and regulatory pathway.

Manufacturing quality controls and consistency.

Post-marketing safety monitoring and compliance with licence conditions.

The exact evidence required depends on the product and the applicable regulatory pathway; a blanket requirement for identical clinical trials for every biosimilar would be inaccurate.

B. Is there a separate US-style interchangeability designation?

The US statutory category should not automatically be imported into Indian law. Indian authorisation as a similar biologic and permission to substitute a product at the pharmacy are separate legal questions.

A marketing authorisation alone should not be treated as proof that every pharmacist may substitute one biologic for another without appropriate professional and legal authority. The applicable product licence, prescribing requirements, institutional protocols and relevant Indian law must be examined.

For India, the crucial questions are therefore:

Has the particular similar biologic been authorised for the relevant indication?

Does the proposed substitution comply with applicable dispensing and prescribing requirements?

Is the change clinically appropriate for the patient?

Are the product, batch and treatment records sufficiently traceable?

Legal caution: A universal, nationally applicable Indian rule identical to the US interchangeable-biosimilar designation should not be assumed without identifying a specific governing provision. The 2025 CDSCO guideline is a regulatory scientific framework, not by itself a comprehensive pharmacy-substitution code.

5. Important case laws and their legal principles

A crucial research point is that the leading reported cases mostly concern biosimilar approval, patent disputes and regulatory procedure—not the scientific interchangeability threshold itself. They must be used for the propositions they actually decided.

Case 1: Sandoz Inc. v. Amgen Inc. (2017)

Supreme Court of the United States · 582 U.S. 1 (2017)

Facts: Sandoz sought FDA approval for Zarxio, a biosimilar to Amgen's Neupogen. The dispute concerned statutory information exchange and the notice required before commercial marketing under the BPCIA.

Decision: The Supreme Court held that the BPCIA did not provide a federal injunction to enforce the information-disclosure requirement at issue. It also held that notice of commercial marketing could be provided before FDA licensure.

Legal principle: The abbreviated approval pathway and its procedural obligations must be interpreted according to the statutory text. Biosimilar market entry is not governed solely by scientific similarity; statutory patent and marketing procedures also matter.

Relevance to interchangeability: The case explains the statutory architecture for biosimilar entry, but it did not establish the clinical switching standard or decide whether a product qualified as interchangeable.

Supreme Court of the United States+1

Case 2: Amgen Inc. v. Sandoz Inc. (Federal Circuit, 2017)

U.S. Court of Appeals for the Federal Circuit · December 14, 2017

Facts: Following the Supreme Court's decision, the parties continued litigating the consequences of compliance with the BPCIA's disclosure and notice provisions.

Decision: The Federal Circuit addressed the statutory remedies and the pre-emption of state-law claims relating to the information-disclosure requirement.

Legal principle: A biosimilar dispute must distinguish between regulatory approval, compliance with federal statutory procedures and the availability of state-law remedies.

Relevance: The decision helps explain the legal environment for biosimilar commercialisation, but it is not a direct judicial test for interchangeable-product designation.

Justia Law+1

Case 3: Amgen Inc. v. Apotex Inc. (2018)

U.S. Court of Appeals for the Federal Circuit · 827 F.3d 1052 (Fed. Cir. 2016) is not the citation for this case; the relevant reported decision is 827 F.3d 1052 for the 2016 Amgen/Sandoz Federal Circuit matter.

Care is necessary when citing biosimilar litigation: several cases involving Amgen, Apotex and Sandoz address different products, procedural issues and patent disputes. They should not be conflated.

For an interchangeability analysis, the primary authority remains PHSA § 351(k)(4) and the FDA's scientific guidance, rather than a general proposition supposedly established by patent litigation.

Case 4: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Supreme Court of the United States · 569 U.S. 576 (2013)

Facts: The case concerned patent eligibility for isolated human genes and complementary DNA, rather than biosimilar substitution.

Decision: The Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated, while synthetically created cDNA may be patent-eligible subject to the applicable requirements.

Legal principle: Biological subject matter can raise distinct questions of scientific characterisation and legal classification.

Relevance: This is a background biotechnology patent case, not an authority on biosimilar interchangeability. It may be relevant to the intellectual-property environment surrounding biological medicines, but it does not establish a substitution threshold.

6. Additional legal principles affecting interchangeability

A. Regulatory evidence and extrapolation

A biosimilar application may rely on a totality of evidence, including analytical, functional, pharmacokinetic, pharmacodynamic, clinical and immunogenicity data as appropriate.

The FDA may permit extrapolation to additional approved indications without a separate clinical study for each indication when the scientific justification is adequate. That is a question of biosimilar approval; it should not automatically be treated as proof that all switching questions have been resolved.

FDA+1

B. Pharmacovigilance and traceability

Interchangeability does not eliminate the need to identify the biological product actually administered.

Good practice includes:

Recording the product name and batch or lot number.

Maintaining records of switching and substitution.

Reporting suspected adverse reactions under applicable rules.

Investigating unexpected loss of efficacy or immunogenicity.

Ensuring that manufacturers and healthcare providers meet their respective safety-reporting obligations.

These safeguards are especially important when a patient receives products from multiple manufacturers over a prolonged treatment course.

C. Product labelling and patient communication

Product labelling must comply with the relevant regulatory requirements. Prescribers and pharmacists should understand the difference between a biosimilar's authorised indications and the legal permission to substitute it.

Where substitution is permitted, communication and recordkeeping requirements vary by jurisdiction. A substitution rule may require notice to the prescriber or patient, subject to applicable exceptions.

7. Important Indian case laws

Indian decisions are particularly relevant because they distinguish the regulatory approval of a similar biologic from the separate legal questions of patent infringement, manufacturing disclosure and product representation.

Case 5: Genentech Inc. v. Drugs Controller General of India (Delhi High Court, 2016)

CS (OS) No. 3284/2015 · Decision dated 25 April 2016

Legal significance: The proceedings addressed disputes concerning biosimilar trastuzumab and the regulatory requirements for demonstrating similarity.

The judgment discusses the scientific distinction between conventional generic drugs and biosimilars. Biosimilars must establish comparability through the applicable regulatory process rather than relying solely on the standards used for chemically synthesised generics.

Principle: A manufacturer cannot treat a biological medicine as an ordinary generic merely because it references an innovator product. Regulatory approval must be supported by the required evidence of similarity, safety and efficacy.

Indian Kanoon+1

Case 6: F. Hoffmann-La Roche Ltd. v. Drugs Controller General of India (Delhi High Court, 2023)

CS(COMM) Nos. 540/2016 and 1119/2016 · Decision dated 11 September 2023

Legal significance: The litigation concerned biosimilar products, regulatory compliance, representations about similarity and the rights of innovator manufacturers.

The court considered claims relating to the approval and marketing of products represented as biosimilars, including questions about whether appropriate comparability testing had been performed.

Principle: Biosimilar status does not remove the obligation to comply with the applicable drug-approval framework or automatically resolve disputes about misleading representations, intellectual property or the adequacy of regulatory evidence.

Relevance: These issues may become important when an interchangeability or substitution claim is challenged, but the decision should not be mischaracterised as creating a separate statutory interchangeability designation equivalent to the US model.

Indian Kanoon+1

Case 7: F. Hoffmann-La Roche AG v. Zydus Lifesciences Ltd. (Delhi High Court, 2024)

CS(COMM) No. 159/2024 · Interim order dated 23 February 2024

Legal significance: The dispute concerned pertuzumab and alleged patent infringement relating to a proposed similar biologic.

The proceedings examined the relationship between regulatory biosimilarity, the reference biologic and the innovator's patent rights.

Principle: Regulatory similarity does not automatically answer the question of patent infringement. The two questions involve different legal standards and evidence.

Relevance: A product may satisfy the regulatory criteria for a similar biologic while still raising independent intellectual-property issues. Conversely, a patent dispute does not by itself establish that a biosimilar fails the regulatory standard.

Indian Kanoon+1

Case 8: F. Hoffmann-La Roche AG v. Zydus Lifesciences Ltd. (Delhi High Court, 2025)

CS(COMM) 159/2024 · Decision dated 23 July 2025

This later decision considered the application of Section 104A of the Patents Act, 1970, in a biological-drug patent dispute.

The judgment addressed the distinction between the comparability standard under biosimilar guidelines and the statutory requirements relevant to the particular patent dispute.

Principle: A biosimilar approval framework does not automatically replace the requirements of patent law. Regulatory similarity and patent-law questions must be analysed independently.

Relevance: The decision is useful for understanding the legal boundaries surrounding biosimilar development and commercialisation. It is not a ruling that establishes the general pharmacy-substitution threshold for biosimilars.

Indian Kanoon+1

Case 9: Zydus Lifesciences Ltd. v. E. R. Squibb & Sons, LLC (Delhi High Court, 2026)

FAO(OS) (COMM) 120/2025 · Decision dated 12 January 2026

The appellate proceedings involved nivolumab-related patent claims and the legal implications of describing a product as a biosimilar.

The court examined whether biosimilarity alone justified an inference that the accused product necessarily possessed the same amino-acid sequence or infringed the asserted patent claims.

Principle: A general claim of biosimilarity cannot replace the evidence required to establish the specific technical and legal elements of patent infringement.

Relevance: This decision illustrates why the legal assessment of biological medicines must remain evidence-based. It concerns patent infringement rather than a general interchangeability designation.

Indian Kanoon+1

8. Comparative legal framework: United States and India

The comparison is grounded in the FDA's statutory guidance and the CDSCO's similar-biologics framework.

FDA+2

9. Practical legal tests for a proposed substitution

Consider a patient receiving a reference monoclonal antibody whose pharmacist is asked to dispense a biosimilar instead.

A legally sound assessment would proceed as follows:

Confirm authorisation. Verify the precise product, manufacturer, formulation, indication and marketing authorisation.

Check substitution authority. Determine whether the jurisdiction permits the proposed substitution without prescriber intervention and whether any restrictions apply.

Assess clinical suitability. Consider the prescribed regimen, administration route, device, dosing and any patient-specific concerns.

Verify the applicable designation. In the United States, check the FDA's Purple Book for the product's biosimilarity and interchangeability status.

FDA+1

Maintain traceability. Record the actual product dispensed and relevant batch information, and comply with applicable communication and adverse-event reporting rules.

The legal result depends on all these elements. Scientific similarity is essential, but it does not independently confer every dispensing right.

10. Legal consequences of failing to meet the threshold

Failure to satisfy the relevant legal or regulatory requirements may lead to several consequences.

Regulatory action: Refusal, suspension or withdrawal of an authorisation where the governing law permits.

Injunctions and patent litigation: Where the facts establish an actionable infringement or other legally recognised ground.

Civil liability: Potential liability for negligence, defective products, misleading representations or other recognised causes of action, depending on the facts and governing law.

Professional or disciplinary consequences: Where a pharmacist or healthcare professional breaches applicable dispensing or professional standards.

Pharmacovigilance obligations: Investigation and reporting of suspected adverse events, including possible treatment failure.

These outcomes are not automatic. Each requires the relevant statutory basis, evidence and procedural safeguards.

11. Critical legal issues and unresolved questions

Several issues continue to matter in biosimilar interchangeability policy.

1. Scientific evidence versus administrative burden. A separate switching-study requirement can provide useful evidence, but unnecessary duplication may delay access to less expensive biologics. Regulators must determine what additional evidence is scientifically justified.

2. Patient autonomy and prescriber authority. Substitution policies should balance access and affordability with the clinical circumstances of the patient and applicable prescribing requirements.

3. Product traceability. Clear identification of the administered product is essential for investigating adverse reactions and determining the cause of a suspected safety signal.

4. Regulatory harmonisation. Different national approaches can complicate the global development and commercialisation of biosimilars. International scientific harmonisation does not, however, automatically harmonise domestic substitution law.

5. Patent law versus regulatory law. A marketing authorisation does not necessarily resolve patent disputes, and patent ownership does not itself establish that a product is scientifically unsuitable for interchangeability.

12. Conclusion

The central legal principle is that biosimilarity, interchangeability and pharmacy substitution are three related but distinct concepts.

In the United States, PHSA § 351(k)(4) expressly establishes the additional interchangeability threshold, including the same-clinical-result and switching-risk criteria. State pharmacy laws then determine the practical conditions for substitution.

In India, the relevant framework centres on the authorisation of similar biologics, comparability requirements and applicable prescribing and dispensing law. Indian courts have emphasised the distinct regulatory and intellectual-property issues surrounding biological medicines, but the cited judgments should not be treated as creating a general US-style interchangeability designation.

The sound legal approach is to verify the product's regulatory status, identify the governing substitution rule, assess clinical suitability and preserve product traceability. A biosimilar's approval alone should not be assumed to resolve every legal question concerning substitution.

Scope note: This is a comparative legal overview for research and educational purposes. A definitive opinion on a particular substitution requires the specific product, jurisdiction and applicable current law.